Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II open-label trial of topical SD 101 for the treatment of chronic wounds and lesions in children with various types of epidermolysis bullosa

Trial Profile

Phase II open-label trial of topical SD 101 for the treatment of chronic wounds and lesions in children with various types of epidermolysis bullosa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allantoin (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2016 According to an Amicus Therapeutics media release, Allantoin has been granted FDA breakthrough therapy designation for the treatment of lesions in patients suffering with Epidermolysis-bullosa in 2013 based on results of this trial.
    • 24 Dec 2013 New trial record
    • 01 Jun 2013 The full data set is expected to be presented at an upcoming scientific conference, according to a Scioderm media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top